- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03046550
Study to Evaluate Safety and PK of NTM-1634 vs Placebo Administered Intravenously in Healthy Adults
A Phase I, Double-Blind, Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of NTM-1634 vs Placebo Administered Intravenously in Healthy Adults
Study Overview
Detailed Description
NTM-1634 drug product is a mixture of four human monoclonal IgG1 antibodies.
This study is a randomized, double-blind, placebo controlled dose escalation study of three dose cohorts. Cohort A: 0.33mg/kg; B: 0.66mg/kg; and C: 1 mg/kg.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Texas
-
San Antonio, Texas, United States, 78209
- ICON Early Phase Services, LLC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Informed consent understood and signed
- Healthy male or healthy, non-pregnant, non-lactating female
- Willingness to comply and be available for all protocol procedures including inpatient confinement for 36 - 48 hours
- Age between 18 and 45 years, inclusive on the day of infusion
- Body Mass Index (BMI) of ≥18.5 and ≤30 kg/m2
If the subject is female and of childbearing potential, she has a negative urine pregnancy test at screening and negative serum test within 24 hours prior to infusion
- Note: A woman is considered of childbearing potential unless post-menopausal (≥ 1 year without menses) or surgically sterilized via bilateral oophorectomy, or hysterectomy or bilateral tubal ligation or successful Essure placement with documented confirmation test at least 3 months after the procedure.
If the subject is female and of childbearing potential, she agrees to practice abstinence from sexual intercourse with men or use acceptable contraception up to visit 12 of the study
- Note: Acceptable contraception methods are restricted to effective devices (Intrauterine Contraceptive Devices , NuvaRing®)
- The hemoglobin, platelet count, white blood cell count and absolute neutrophil count are within normal limits
The urine dipstick results on protein, glucose and blood are negative or trace
- Note: Menstruating females failing inclusion criteria due to a positive blood on urine dipstick may be retested following cessation of menses.
Chemistry screening laboratory tests as outlined in Section 7.5.1.4 are in the normal reference range
- Note: The following exceptions to laboratory normal reference ranges are allowed: Creatinine, Blood Urea Nitrogen (BUN), total bilirubin, AST, ALT, lipase, amylase, Prothrombin Time (PT), Partial Thromboplastin Time (PTT) below the lower limit of normal (LLN); CK less than 400mg/ml; Glucose, potassium, total protein, and alkaline phosphatase with a toxicity grade of 1 is allowable; albumin above the upper limit of normal (ULN).
- Laboratory values that are outside the range of eligibility but are thought to be due to an acute condition or due to laboratory error may be repeated once.
- Abnormalities in mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), red cell distribution width (RDW), mean platelet volume (MPV), and nucleated red blood cell count (NRBC CT), which are included in a complete blood count with differential, will not be exclusions.
- Has adequate venous access for the infusion
- The urine drug screen is negative
- Breathalyzer test is negative
- Available for follow-up for the duration of the study
- Agrees not to participate in vigorous activity 72 hours prior to dosing through day 15 post dosing
Exclusion Criteria:
History of a chronic medical condition that would either interfere with the accurate assessment of the objectives of the study or increase the risk profile of the subject.
- Note: Chronic medical conditions include diabetes; Asthma requiring use of medication in the year before screening; Autoimmune disorder such as lupus, Wegener's, rheumatoid arthritis, thyroid disease; Coronary artery disease; Chronic hypertension; History of malignancy except low-grade (squamous and basal cell) skin cancer thought to be cured; chronic renal, hepatic, pulmonary, or endocrine disease (except previous asthma which has required no treatment for the past year);
History of severe allergic reaction of any type to medications, bee stings, food, or environmental factors or hypersensitivity or reaction to immunoglobulins.
- Note: Severe allergic reaction is defined as any of the following: anaphylaxis, urticaria, or angioedema
- A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 milliseconds)
Clinically significant abnormal electrocardiogram at screening.
- Note: Clinically significant abnormal ECG results include: complete left or right bundle branch block; other ventricular conduction block; 2nd degree or 3rd degree atrioventricular (AV) block; sustained ventricular arrhythmia; sustained atrial arrhythmia; two Premature Ventricular Contractions in a row; pattern of ST elevation felt consistent with cardiac ischemia; or any condition deemed clinically significant by a study investigator
- Positive serology results for HIV, HBsAg, or HCV antibodies
- Febrile illness with temperature ≥38°C within 7 days of dosing
- Pregnant or breastfeeding
- Donated blood within 56 days of enrollment
- Known allergic reactions to any of the study product components present in the formulation or in the processing, as listed in the Investigator Brochure
- Treatment with another investigational drug within 28 days of dosing
- Treatment with a monoclonal antibody at any time
- Receipt of antibody (e.g. TIG, VZIG, IVIG, IM gamma globulin) or blood transfusion within 6 months or within 5 half-lives of the specific product given
- Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements
- Use of H1 antihistamines or beta-blockers within 5 days of dosing
Use of any prohibited medication within 28 days prior to study entry or planned use during the study period
- Note: Prohibited medications include immunosuppressives (except Nonsteroidal Anti-Inflammatory Drugs [NSAIDS]); immune modulators; oral corticosteroids (topical/intranasal steroids are acceptable); anti-neoplastic agents; any vaccine (licensed or investigational)
- Previous exposure to botulinum toxin, receipt of antibodies against botulinum toxin, or previous treatment with equine antitoxin
- Any previous injection or planned injection within 4 months after enrollment of botulinum toxin for cosmetic reasons, spastic dysphonia, torticollis, or any other reason
- Any specific condition that in the judgment of the investigator precludes participation because it could affect subject safety
Plans to enroll or is already enrolled in another clinical trial* that could interfere with safety assessment of the investigational product at any time during the study period
- Note: Includes trials that have a study intervention such as a drug, biologic, or device
Is a study site employee or staff
- Note: Site employees or staff include the PIs and sub-investigators or staff who are supervised by the PI or Sub-Investigators
- Systolic blood pressure >140mm Hg or diastolic blood pressure >90 mm Hg
- Resting hear rate <50 or >100 beats per minute
- Oral temperature ≥ 38°C (100.4°F)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: SEQUENTIAL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Cohort A
Cohort A will have 8 total subjects.
6 subjects will receive 0.33 mg/kg of NTM-1634 and 2 subjects will receive placebo.
|
placebo
NTM-1634 drug product is a mixture of four human monoclonal IgG1 antibodies.
Three dose cohorts (A: 0.33 mg/kg B: 0.66 mg/kg, and C: 1 mg/kg).
|
EXPERIMENTAL: Cohort B
Cohort B will have 8 total subjects.
6 subjects will receive 0.66 mg/kg of NTM-1634 and 2 subjects will receive placebo.
|
placebo
NTM-1634 drug product is a mixture of four human monoclonal IgG1 antibodies.
Three dose cohorts (A: 0.33 mg/kg B: 0.66 mg/kg, and C: 1 mg/kg).
|
EXPERIMENTAL: Cohort C
Cohort C will have 8 total subjects.
6 subjects will receive 1 mg/kg of NTM-1634 and 2 subjects will receive placebo.
|
placebo
NTM-1634 drug product is a mixture of four human monoclonal IgG1 antibodies.
Three dose cohorts (A: 0.33 mg/kg B: 0.66 mg/kg, and C: 1 mg/kg).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The occurrence of Serious Adverse Events following administration of NTM-1634 to the final follow-up visit
Time Frame: 121 days
|
number of SAE
|
121 days
|
The occurrence of Adverse Events from administration of NTM-1634 to Day 57
Time Frame: 57 days
|
number of AE
|
57 days
|
The occurrence of changes from baseline in physical examination following administration of NTM-1634 to the final follow-up visit
Time Frame: 121 days
|
types of changes of physical exam findings
|
121 days
|
The occurrence of changes from baseline in vital signs following administration of NTM-1634 to the final follow-up visit
Time Frame: 121 day
|
change in vital signs
|
121 day
|
The occurrence of changes from baseline in clinical safety laboratory values following administration of NTM-1634 to the final follow-up visit
Time Frame: 121 day
|
change in lab values
|
121 day
|
The occurrence of changes from baseline in ECG parameters post administration of NTM-1634 on Day 1 (day of infusion)
Time Frame: 1 day
|
changes in ECG parameters
|
1 day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The assessment of Cmax for each of the four monoclonal antibodies of NTM-1634
Time Frame: 121 days
|
Cmax assessments
|
121 days
|
The assessment of Tmax for each of the four monoclonal antibodies of NTM-1634
Time Frame: 121 days
|
Tmax assessments
|
121 days
|
The assessment of AUC(0-t) for each of the four monoclonal antibodies of NTM-1634
Time Frame: 121 days
|
AUC(0-t) assessments
|
121 days
|
Development of human anti-human antibodies (HAHA) via blood collection at Days 1, 29, 57, 91 and 121.
Time Frame: Days 1, 29, 57, 91, and 121
|
antibody development
|
Days 1, 29, 57, 91, and 121
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Dennis Ruff, MD, ICON Early Phase Services, LLC
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- NTM-1634-001
- 272201600009C-2-0-1 (NIH)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States